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Abstract
·AIM: To assess the effect of topical bevacizumab use
on postoperative pterygium recurrence in eyes who
underwent pterygium excision with limbal -conjunctival
autograft transplantation (LCAT).
· METHODS: eighty -eight eyes of 88 patients with
primary pterygium were included. Pterygia were graded
preoperatively from type 1 to type 3 (type 1 atrophic, type
3 inflamed) according to the inflammatory status. The
eyes were preoperatively randomized to receive topical
steroid and antibiotic treatment (group 1, 46 eyes) and
additional topical bevacizumab (5 mg/mL; group 2, 42
eyes) in the postoperative period. All eyes underwent
pterygium excision and LCAT. Medications were tapered
and discontinued at one month. Postoperative
complications and recurrence rates were recorded.
·RESULTS: The mean follow -up duration was 29.3 依
4.2mo (24-52mo) and 28.5依3.4 (24-48mo) in group 1 and
2, respectively ( 跃0.05). There were no statistically
significant differences regarding the age or gender
between groups ( 跃0.05). Also, the difference between
groups with respect to pterygium type was not
significant. During the follow -up period, recurrence
developed in 2 eyes (4.3%) in group 1, whereas in one
eye (2.4% ) in group 2. No statistically significant
difference between groups was found in recurrence rates
( 跃0.05). No re-operation for recurrence was necessary
during the follow-up period in both groups.
·CONCLUSION: Topical bevacizumab seems to have no
additonal effect on pterygium recurrence after LCAT.
· KEYWORDS: limbal-conjuctival autograft; topical
bevacizumab; pterygium; recurrence; topical bevacizumab
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INTRODUCTION
P terygium, histopathologically characterized by elastoticdegeneration of collagen and fibrovascular proliferation,
is a very common conjunctival degenerative condition.
Current treatment for pterygium focuses on surgical excision
and prevention of recurrence. Conjunctival autografting after
pterygium excision is associated with very low rates of
recurrence and complications when compared to other
surgical techniques. The surgeon's skill and experience affect
the recurrence rate, which varies between 2% and 39% with
this technique[1,2].
In the literature, some medical approaches were also used
intraoperatively and postoperatively to prevent the recurrence
including adjunctive therapy with beta radiation, thiotepa,
mitomycin C, 5-fluorouracil, and corticosteroids (
triamcinolone) [3-7]. However, the value of such therapy is
limited because of potential ocular side effects, such as
increased intraocular pressure, secondary bacterial infection,
scleral ulceration, poor epithelial healing, and superficial
punctate keratitis.
Several studies suggest that vascular endothelial growth
factor (VEGF) plays an important role in the development of
pterygium. Furthermore, VEGF has been identified in the
epithelium of pterygium [8-12]. The overexpression of VEGF in
pterygium tissue led us to consider to evaluate the role of
anti-VEGF therapy, which could induce regression of blood
vessels and hence retard progression of pterygium.
Bevacizumab (Avastin; Roche, USA) is a recombinant
humanized monoclonal antibody against VEGF that
neutralizes all isoforms of human VEGF and inhibits
VEGF-induced proliferation of endothelial cells[13,14]. To date,
several studies regarding the use of topical or subconjunctival
bevacizumab as an off-label treatment for pterygium have
been published [15-19]. Nonetheless, the results remain
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inconclusive. Our study is the first randomized controlled
trial that evaluated the effect of topical bevacizumab on
postoperative recurrence after pterygium surgery with
limbal-conjunctival autograft transplantation (LCAT).
SUBJECTS AND METHODS
Eighty-eight consecutive patients (88 eyes) with primary
nasal pterygium were enrolled in this prospective study.
Patients with immune system, eyelid or ocular surface
diseases ( blepharitis, Sj觟gren syndrome and dry eye), and
a history of ocular surgeries within the previous 6mo were
excluded from the study. All patients were informed about
the design of the study and the procedure, and written
informed consent was obtained from all patients. The study
adhered to the tenets of the Declaration of Helsinki, and was
approved by the Ethics Committee at Baskent University
Faculty of Medicine (KA 11/34).
Patients were randomized into two groups. Randomization
was accomplished by a list created by a random-number
generator. One eye of each patient was included in the study.
If the patient had bilateral pterygium, one eye was selected
randomly and included in the study.
The pterygia were graded according to the grading system
developed by Tan [20] as grade 1 (atrophic) with
episcleral vessels under the body of the pterygium not
obscured and clearly distinguishable; grade 3 (fleshy),
episcleral vessels totally obscured; or grade 2 (intermediate),
all other pterygia not falling into grades 1 or 3 (Figure 1).
The pterygia extended at least 3 mm beyond the limbus in all
cases.
To ensure consistency, all operations were performed under
an operating microscope by the same surgeon (AK). After
administration of topical 0.5% proparacaine hydrochloride
(HCL) (Alcaine , Alcon , Switzerland) , lidocaine HCL
40 mg/2 mL+epinephrine 0.025 mg/mL (Jetokain, Adeka,
Turkey) was injected under the conjunctiva at the
superotemporal bulbar region and into the body of the
pterygium. The head of the pterygium was excised
completely from the cornea, and the body was dissected and
excised with conjunctival scissors. Abnormal scar tissue on
the corneal surface was polished. Minimal cauterization was
used to control bleeding. Graft transplantation was carried
out after calculating the size of the defect (mm2) and
determining the correct size (oversized by 1 mm horizontally
and vertically compared with the bare sclera defect).
Conjunctival autografts were taken from the superior
temporal conjunctiva to have a large area for harvesting an
appropriate-size graft and to achieve a more cosmetically
acceptable appearance in the operated eye as a result of the
coverage of the donor site by the upper lid. We were careful
to place the limbal edge of the graft at the host limbal tissue.
The graft was subsequently moved to the nasal area and
attached to the conjunctival edges and episclera with fibrin
glue (Tisseel, Baxter, USA) in all cases. The eye was covered
with an eye pad after administration of topical antibiotic
ointment (Tobrex, Alcon).
Postoperatively, 46 patients (46 eyes, group 1) received
dexamethasone 0.1% (Maxidex, Alcon) and tobramycin 0.3%
(Tobrex, Alcon) eye drops. The medications were tapered over
the course of four weeks. In group 2 (42 eyes), additional 5
mg/mL topical bevacizumab was used four times daily for
one month postoperatively. These drops were prepared from
the commercial bevacizumab solution (25 mg/mL Avastin,
Genentech, USA) under sterile conditions and stored in
sterile vials at +4℃ for 48h. Patients were examined on the
first postoperative day, weekly until one month, and monthly
thereafter. Postoperative complications and recurrence rates
were recorded. Recurrence was defined as any fibrovascular
growth that passed the corneal limbus by more than 1mm.
Statistical Analysis To determine the sample size, 琢=0.05
and power=80% (1-茁=0.80) were accepted. The minimum
sample size as calculated using the PASS statistical software
program (NCSS, Kaysville, UT, USA). Assessment for
normal distribution of the data was performed with the
D'Agustino-Pearson test. The Student test for independent
samples was used to compare parametric data and the
Mann-Whitney U test was used for unpaired nonparametric
data by using SPSS version 13.0 (SPSS Inc., Chicago,
Illinois, USA). values less than 0.05 were considered
significant.
RESULTS
The demographic data are summarized in Table 1. There
were no statistically significant differences between the two
groups with regard to age and sex ( =0.311, =0.534,
respectively).
The mean follow-up period was 29.3依4.2mo (24-52mo) in
Figure 1 The preoperative grading of the pterygia Grade 1
(top) refers to episcleral vessels under the body of the pterygium not
obscured and clearly distinguishable, grade 3 (bottom) to episcleral
vessels totally obscured and grade 2 (middle) to all other pterygia
not falling into grades 1 or 3.
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group 1 and 28.5 依3.4 (24-48mo) in group 2, and the
difference was not statistically significant ( =0.621) (Table 1).
Also, the difference between groups with respect to
pterygium type was not significant. In both groups, type 2
pterygium was the most common type ( =0.826) (Table 2).
Figures 2 and 3 show the postoperative appearances of the
patients at the first postoperative day, the first week and 6th
month in group 1 and group 2 additional bevacizumab
therapy, respectively. Pterygium recurrence was observed in
2 eyes (4.3%) in group 1, and in one eye (2.4%) in group 2.
No statistically significant difference between groups was
found regarding to recurrence rates ( =0.092, Table 1). The
recurrences occurred at the third and fourth month in group 1
and at the fourth month in group 2. The preoperative grades
of these recurrent pterygia were grade 2 in both groups. The
recurrent cases were closely followed-up for continuing
growth of fibrovascular tissue onto the cornea. No
reoperation was necessary during the follow-up period in
both groups.
Topical bevacizumab was well tolerated in all patients. No
irritation, burning, and/or any systemic side effects of
bevacizumab were reported by the patients during the
follow-up period.
DISCUSSION
Inflammation and fibrovascular proliferation are important
factors in the pathogenesis of the pterygium which is a
degenerative process. The extent and severity of the
fibrovascular growth of pterygium seem to comprise a
reliable morphologic index for predicting recurrence after
surgery [20]. Several methods have been proposed to reduce
the recurrence rate, but none has been shown to be superior
to the other.
Several active angiogenic and epithelial growth factors
including fibroblast growth factor, heparin-binding epidermal
growth factor, and connective tissue growth factor contribute
in the fibrovascular pathogenesis of pterygium. However,
VEGF, which has been shown to be significantly increased in
the excised pterygium tissues, plays the main role[11]. It is also
well-known that VEGF is the key factor in wound healing
response. It is found to be elevated in active wounds and it
plays a role in the fibroblast and inflammatory cell migration
through acting as a signal transducer [21]. Thus, VEGF has
been the primary target of many current antiangiogenic
therapies and hence, by blocking VEGF, the remodeling and
wound healing process the postoperative period of pterygium
Figure 2 Postoperative photographs of a patient in group 1
(topical steroid) A: The graft is in place at postoperative 1d; B:
There is no graft displacement and the vascularization is greatly
reduced at postoperative 7d; C: A normal conjunctival healing
without any recurrence at postoperative 6th month.
Figure 3 Postoperative photographs of a patient in group 2
(topical steroid and bevacizumab) A: The appearance at
postoperative 1d showing subconjunctival hemorrhage and slight
graft edema; B: The subconjunctival hemorrhage is reduced and the
graft is healthy at 7d; C: There is no recurrence at postoperative 6th
month.
Table 1 Patients’ demographics, follow up periods and recurrence rates in two groups 
 Parameters Group 1 (steroid) n=46 
Group 2 (steroid+bevacizumab) 
n=42 P 
Gender(M/F) 21/25 22/20 0.534 
Age (a)  53.04±11.81 58.82±12.02 0.311 
Follow-up (mo) 29.3±4.2 28.5±3.4 0.621 
Recurrence rate 2 (4.3 %) 1 (2.4 %) 0.092 
 
Table 2 Pterygium types in two groups 
Types Group 1 (steroid)  n=46 
Group 2 (steroid+ 
bevacizumab) n=42 P 
Type 1 11 (24%) 7 (17%) 0.213 
Type 2 22 (48%) 21 (50%) 0.826 
Type 3 13 (28%) 14 (33%) 0.534 
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would be also changed and recurrence rate may be reduced
as a result of reduction of fibrovascular tissue formation.
There have been several studies on the use of bevacizumab in
primary and recurrent pterygia. Main treatment approaches
included subconjunctival and intralesional injection of the
drug as well as topical administration to reduce the
recurrence rate or to inhibit an impending recurrent
pterygium. Also, brief reports and controlled trials were
published about intralesional injections of the drug without
any surgery [17,22]. Main outcome measures were the reduction
in size in short term, but the effect of bevacizumab was not
found to be clinically significant in these studies. Bahar and
co-authors [19] reported that there were neither ocular or
systemic adverse effects in patients treated with
subconjunctival bevacizumab for recurrent pterygium, nor
beneficiary effects seen on regression of corneal
neovascularization. Razeghinejad [16] reported single
dose of intraoperative subconjunctival bevacizumab injection
in 30 eyes of 30 patients who underwent primary pterygium
excision with rotational flap application and did not find any
effect on the recurrence rate. Lekhanont [23] have
conducted a randomized controlled study in patients with
impending recurrent pterygia. They have applied three
different dosages of bevacizumab with subconjunctival route,
which showed no beneficial effects on the regression of the
lesions or on the recurrence rate, but only a transient decrease
in the conjunctival vascularization was observed. Ozgurhan
[24] applied topical bevacizumab as adjunctive therapy
1mo after conjunctival autograft surgery for recurrent ptergia
and found that the drug was safe and effective to prevent
corneal neovascularization. But they did not find statistically
significant effect on the recurrence rate .
Uy [25] has applied topical bevacizumab in 2 Steven
Johnson cases with corneal neovascularization and they
reported that the drug was well tolerated and induced
regression of ocular surface neovascularization, conjunctival
injection, and corneal opacification. In another study by
Manzano 26], the effect of topical bevacizumab on
experimental corneal neovascularization in rats was studied.
They reported that 4 mg/mL topical administration of
bevacizumab had decreased corneal neovascularization by
40% following chemical injury.
Wu [18] reported having success with topical
bevacizumab in a patient suffering from impending recurrent
pterygium. Fallah and coauthors [15] also reported that short
term use of topical bevacizumab was effective in delaying of
recurrence of impending pterygia in a study including 54
patients. However, the use of mitomycin C in their study
might be an additive factor in the inhibition of recurrence.
Conjunctival autografting is considered the most effective
technique of preventing recurrence [20,28]. Although it is safe
and effective, more surgical expertise, technical ability, and
surgical time are needed to secure the grafts with sutures [28].
Earlier studies with the use of fibrin-based adhesives for
attaching conjunctival grafts in pterygium surgery showed
that this technique reduces the surgery time, suture-related
complications and patient discomfort [19,29-31]. In the current
study, we performed pterygium excision and LCAT and used
fibrin glue for fixation of the autograft in both groups. In our
knowledge, this study is the first prospective, randomized
clinical trial with long-term follow-up in the literature.
Moreover, the lack of any significant difference between
groups in patient age and preoperative pterygium type which
may have an effect on the recurrence rates, strengthens the
credibility of the results.
In conclusion, topical bevacizumab was well tolerated as an
additional therapy after pterygium surgery with autografting.
The drug did not have any side effects on wound healing or
epithelization. However, the recurrence rate seems to be
unaffected despite one month topical bevacizumab therapy.
Bevacizumab seems to have no beneficial effect on lowering
the recurrence of primary ptergia when used topically after
operation.
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